Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Human angiogenin (Ang) is a tumor-promoting RNase in the pancreatic RNase superfamily. Efforts to develop nucleotide-based inhibitors of Ang as potential anticancer drugs have been hampered by the lack of direct structural information on Ang-nucleotide complexes. Here, we have used heteronuclear NMR spectroscopy with (15)N- and (15)N/(13)C-labeled Ang to map the interactions of Ang with the phosphate ion, seven adenosine mononucleotides (the 2'-, 3'-, and 5'-monophosphates, the 2',5'- and 3',5'-diphosphates, the 5'-diphosphate, and the 2'-monophospho-5'-diphosphate), and the dinucleotide 2'-deoxyuridine 3'-pyrophosphate (P' --> 5') adenosine-2'-phosphate (dUppA-2'-p). The 2'-phosphate based derivatives, which bind more tightly than the corresponding 3'-phosphate isomers, induced characteristic large resonance perturbations of the backbone amide proton of Leu(115), the backbone (15)N of His(114), and the Gln(12) side-chain NH(2) group in the Ang active site. In contrast, adenosine derivatives with only 3'- or 5'-phosphates produced much less dramatic perturbations of Leu(115) and His(114) resonances, along with modest perturbations of additional residues both within and beyond the active site. Measurements of NOEs together with molecular docking analyses revealed the three-dimensional structures of the complexes of Ang with adenosine 2',5'-diphosphate and dUppA-2'-p; the binding modes of these inhibitors differ substantially from those predicted in earlier studies. Most notably, the 2'-phosphate rather than the 5'-phosphate occupies the P(1) catalytic subsite of Ang, and the side chain of His(114) has undergone a conformational transition that positions it outside P(1) and allows it to form stacking interactions with the adenine ring of the inhibitor. Strikingly, the 2'-deoxyuridine moiety of dUppA-2'-p makes only a few contacts with Ang, and these involve residues outside the B(1) subsite where the pyrimidine ring of substrates normally binds.
D000227:Adenine Nucleotides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D001665:Binding Sites; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006639:Histidine / Q000737:chemistry; D006801:Humans; D007700:Kinetics; D007930:Leucine / Q000737:chemistry; D008958:Models, Molecular; D019906:Nuclear Magnetic Resonance, Biomolecular; D010710:Phosphates / Q000378:metabolism; D011485:Protein Binding; D012259:Ribonuclease, Pancreatic / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D012260:Ribonucleases / Q000037:antagonists & inhibitors*
D000227:Adenine Nucleotides; D004791:Enzyme Inhibitors; D010710:Phosphates; D006639:Histidine; D012260:Ribonucleases; C046366:angiogenin; D012259:Ribonuclease, Pancreatic; D007930:Leucine